The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.
Participants will divided in to three groups.
* Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.
Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.
Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.
Age range: 50-85 years
Patients who have previously used antiplatelet drugs.
Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)
Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.
Patient with a history of intravitreal anti-VEGF injection or macular laser.
Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.
Parallel
Aspirin 81Mg Ec Tab
DrugPatients take aspirin 81 mg per day.
Clopidogrel
DrugPatients take clopidogrel 75 mg per day.
N-acetylcysteine
DrugPatients are given N-acetylcysteine 600 mg per day.
Drusen volume analysis
To assess AMD progression in patient with large drusen, drusen volume was measured and analyzed in each patient group by OCT scan
Best-corrected visual acuity change
To evaluate Best-corrected visual acuity in each patient group by ETDRS chart
Rate of disease progression
To evaluate disease progression to geographic atrophy or neovascular AMD by OCT scan and fundus photo
Side effects of medications intake
To evaluate the safety of the medication used by questionnaire
Click on the lead sponsor to view all of their trials.
